Clik here to view.
New ways of seeing, new ways of saying: a New Year for pharma
The familiar rituals of festive celebration can be a comfort to many, and prudent hosts remember that such occasions are not a time for innovation. Family, friends and guests are more likely to enjoy...
View ArticleClik here to view.
Top pharma companies in social media: whose opinion are we polling?
PatientView pharma corporate reputation 2012 vs. 2011: final rankings (reproduced with permission) Millions of words have been written over recent years across media channels about the relative...
View ArticleClik here to view.
Pharma and the pataphysics of social health
It’s easier to sharpen a pencil than it is to write a poem with it. It’s easier to clean a musical instrument than it is to play a sonata on it. It’s easier to talk about technology in healthcare than...
View ArticleClik here to view.
Social health and distributed value: a radiant future
The recently heralded demise of Google Reader will precipitate a slew of sardonic posts from commentators across industries who will deride us in colourful terms for our short-sightedness in having...
View ArticleClik here to view.
Next: looking beyond the device in digital health
Observers of the digital health ecosystem seem addicted to the idea that it is accretive when in truth it is commutative. News of the demise of sleep tracker Zeo, the closure of Google Reader through...
View ArticleClik here to view.
The best digital health app is conversation
Although our attention may be distracted from time to time by a health-related smartphone or tablet app, a health tracking device, a quantified self peripheral, or some other piece of shiny,...
View ArticleClik here to view.
Will we only truly own our health behaviours when we no longer record them...
I had an interesting conversation on LinkedIn with Johnathan Reid the other day, and it went something like this: Johnathan observed: I do wonder about the negative aspect of data streams from ‘worried...
View ArticleClik here to view.
Nobody talks about pharma the way pharma talks about itself
Having to endure an encounter with another dreary batch of lifeless communications about ‘multi-channel marketing’, ‘patient strategies’, and ‘market access’ isn’t the way that anyone working in the...
View ArticleClik here to view.
Four reasons why pharma isn’t afraid of social media
What are really asking in posing the question ‘is pharma afraid of social media?‘ For once, we’ll disregard the usual preliminary objections concerning the identity of the companies we assume we are...
View ArticleClik here to view.
For pharma, the era of multi-channel marketing, closed loop marketing, sales...
If health has a currency beyond the improvement of outcomes, it is trust. Most participants in the health conversation on the Social Web are happy to agree about the importance of augmenting trust by...
View ArticleClik here to view.
#Pharma100 degrades the health conversation on the Social Web
I’ve written before about my dislike of #pharma100. In my opinion, the embarrassing begging and pleading for votes across social platforms, in public and by direct message, heaps shame upon both...
View ArticleClik here to view.
AstraZeneca takes a personal approach to connecting with patients’ wallets
Within the discussion around AstraZeneca’s branded approach to YouTube, I’ve yet to see any commentary focusing on the fact that whilst the AstraZeneca’s Health Connections blog states that...
View ArticleClik here to view.
Three definitions of influence
Alex Butler, Faisal Ahmed and myself were joined by John Nosta yesterday for an interesting discussion around the subject of influence which has now been published as a Digitally Sick podcast. It’s a...
View ArticleClik here to view.
Boehringer’s ‘Thanks to our 50K facebook likes’ video: a review
I’ve written before about how I enjoy Boehringer’s work on the social web. In the past, the company has delivered some case study-worthy examples as to how a pharma company may present itself...
View ArticleClik here to view.
Pharma-hosted tweet chats at professional congresses: Boehringer’s #COPDchat...
Following on from the #ChatAFib Boehringer organised at this year’s ESC, the company has today announced that it will hold #COPDchat at ERS 2013. It’s great that Boehringer are committing to running...
View ArticleClik here to view.
Pharma needs to let its digital evangelists off the leash
Reproduced with the permission of the author. Tagged: GSK, Merck, pharma
View ArticleClik here to view.
Pharmaceutical marketing in the postmarketing age
Few publications that consider the pharmaceutical industry’s participation in digital environments neglect to mention ‘marketing’ in some capacity. We genuflect to ‘marketing’ so freely, deploy it in...
View ArticleClik here to view.
Seductive repetition
This holiday season, I elected to take a digital sabbatical from 13 December to 2 January. Returning to the healthcare conversation after three weeks away has been… a little odd. The thing that strikes...
View ArticleClik here to view.
Three obstacles to change in healthcare
Yesterday What’s so bad about what happened yesterday? If you’re lucky, nothing at all. However, nothing particularly extraordinary probably occurred either. And therein lies the problem. The routine...
View ArticleClik here to view.
Influence comes from the bottom, and four other new business maxims
It’s an ongoing process, but it is becoming clearer day by day that the dominant business practices that direct the activities of the pharmaceutical industry, among many others, are not merely simply...
View Article
